Information:
Error:
ID
13874
Description
Feasibility and Toxicity of Degarelix for Prostate Downsizing Prior to Permanent Seed Prostate Brachytherapy; ODM derived from: https://clinicaltrials.gov/show/NCT01446991
Link
https://clinicaltrials.gov/show/NCT01446991
Keywords
Versions (1)
- 3/13/16 3/13/16 -
Uploaded on
March 13, 2016
DOI
To request one please log in.
License
Creative Commons BY 4.0
Model comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
Eligibility Prostate Cancer NCT01446991
Eligibility Prostate Cancer NCT01446991
- StudyEvent: Eligibility
Similar models
Eligibility Prostate Cancer NCT01446991
- StudyEvent: Eligibility
Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
prostate cancer
Item
histologic diagnosis of prostate cancer
boolean
C0600139 (UMLS CUI [1])
tumor stage; gleason score; prostate specific antigen
Item
favorable risk disease (ct1 or t2a, gleason score (gs) 6, and prostate specific antigen (psa) < 10 ng/ml)
boolean
C1300072 (UMLS CUI [1])
C3203027 (UMLS CUI [2])
C0138741 (UMLS CUI [3])
C3203027 (UMLS CUI [2])
C0138741 (UMLS CUI [3])
tumor stage; gleason score; prostate specific antigen
Item
low-tier intermediate risk disease (ct2c,gs=6,and psa 10-15 ng/ml, or gs=7 and psa < 10 ng/ml)
boolean
C1300072 (UMLS CUI [1])
C3203027 (UMLS CUI [2])
C0138741 (UMLS CUI [3])
C3203027 (UMLS CUI [2])
C0138741 (UMLS CUI [3])
Antiandrogen therapy; positive biopsy cores; tumor stage; gleason score; prostate specific antigen
Item
intermediate risk disease and androgen deprivation therapy recommended by the treating physician for oncologic reasons such as (≥ 50% positive biopsy cores,ct2c,psa 15-20 ng/ml,gs=7)
boolean
C0279492 (UMLS CUI [1])
C1276779 (UMLS CUI [2])
C1300072 (UMLS CUI [3])
C3203027 (UMLS CUI [4])
C0138741 (UMLS CUI [5])
C1276779 (UMLS CUI [2])
C1300072 (UMLS CUI [3])
C3203027 (UMLS CUI [4])
C0138741 (UMLS CUI [5])
trans-rectal ultrasound prostate volume for prostate brachytherapy; androgen ablation
Item
patient requires baseline planning trans-rectal ultrasound for the purposes of prostate brachytherapy, showing prostate volume > 40 ml and pubic arch interference (not required for those requiring androgen ablation for oncologic reasons)
boolean
C0812546 (UMLS CUI [1])
C1515985 (UMLS CUI [2])
C1515985 (UMLS CUI [2])
serum testosterone
Item
castrate serum testosterone level
boolean
C0428413 (UMLS CUI [1])
pelvic radiotherapy
Item
previous or concurrent pelvic radiotherapy
boolean
C0436276 (UMLS CUI [1])
informed consent
Item
unable to give written informed consent
boolean
C0021430 (UMLS CUI [1])
prostate brachytherapy; Antiandrogen therapy
Item
contraindications to permanent seed prostate brachytherapy or to androgen deprivation therapy
boolean
C0854662 (UMLS CUI [1])
C0279492 (UMLS CUI [2])
C0279492 (UMLS CUI [2])
Study Subject Participation Status
Item
prior treatment for prostate cancer
boolean
C2348568 (UMLS CUI [1])
Transurethral Resection of Prostate
Item
prior trans-urethral resection of the prostate
boolean
C0040771 (UMLS CUI [1])
therapy 5-alpha Reductase Inhibitors Androgen Antagonists; Luteinizing Hormone-releasing Hormone Agonist
Item
previous therapy with a 5-α reductase inhibitor, anti-androgen agent, or lhrh agonist
boolean
C0087111 (UMLS CUI [1,1])
C2936788 (UMLS CUI [1,2])
C0002842 (UMLS CUI [1,3])
C1518041 (UMLS CUI [1,4])
C2936788 (UMLS CUI [1,2])
C0002842 (UMLS CUI [1,3])
C1518041 (UMLS CUI [1,4])
therapy degarelix
Item
previous therapy with degarelix
boolean
C0087111 (UMLS CUI [1,1])
C1455035 (UMLS CUI [1,2])
C1455035 (UMLS CUI [1,2])